Heparin-Induced Thrombocytopenia
On this page
Direct answer
Stopping every source of heparin — infusions, flushes, heparin-coated catheters, low-molecular-weight prescriptions — and switching to a non-heparin anticoagulant is the entire management of heparin-induced thrombocytopenia, and it cannot wait for confirmatory testing. The syndrome is immune (type II): antibodies to platelet factor 4-heparin complexes that paradoxically cause thrombosis, the highest thrombotic risk of any drug reaction. Platelets typically fall more than 50 percent from baseline between days 5 and 10 of exposure, or within 24 hours if heparin was given in the preceding weeks. Warfarin must not be started until platelets recover, because premature vitamin K antagonism causes venous limb gangrene and skin necrosis.
What you must remember
- Timing rules: classic onset day 5-10 of heparin; rapid onset within 24 hours with recent prior exposure (antibodies persist for weeks to about 100 days); delayed onset can appear days after heparin stops.
- Depth of fall: a drop exceeding 50 percent of baseline — the absolute count rarely falls below 20 x 10^9/L, a useful contrast with DIC and with heparin-induced bleeding syndromes.
- 4Ts score: thrombocytopenia degree, timing of onset, thrombosis or skin sequelae, and other causes excluded — a low score usefully rules out the diagnosis; intermediate or high scores send the PF4 ELISA with serotonin release assay as confirmatory gold standard.
- Thrombosis pattern: venous predominance — deep vein thrombosis and pulmonary embolism — plus adrenal vein thrombosis causing haemorrhagic necrosis and addisonian crisis, skin necrosis at injection sites, and arterial limb ischaemia.
- Non-heparin anticoagulants: argatroban (hepatic clearance — ideal in renal failure; prolongs INR artefactually), bivalirudin, fondaparinux (renal clearance), and increasingly direct oral anticoagulants per emerging guidance.
- Warfarin discipline: start only once platelets have recovered (at least 150 x 10^9/L is the conventional threshold), overlap at least five days with the parenteral agent — the mechanism of the gangrene trap is protein C depletion accelerating thrombosis while skin and limbs necrose.
- Duration: three to six months if thrombosis occurred; two to four weeks for isolated HIT; and heparin re-exposure is possible months to years later once antibodies have cleared, as in future cardiac surgery.
A typical exam case
A 64-year-old man on enoxaparin after hip replacement develops new leg swelling on day 6, with platelets fallen from 280,000 to 96,000. The sequence: compute the 4Ts (fall greater than 50 percent, day 6 timing, new thrombosis, plausible alternative excluded — high score), stop all heparin including the prophylactic injection he is still receiving, start argatroban or fondaparinux immediately, and send PF4 antibody testing with the serotonin release assay for confirmation. Do not bridge to warfarin on day 6 — that is the planted error; warfarin waits for platelet recovery with a five-day overlap. Doppler confirms the deep vein thrombosis, which extends his anticoagulation course to three to six months. The case compresses the three decisions the exam samples: recognise, substitute, and sequence the switch correctly.
Where students slip and the Indian reality
The recurring slips: mistaking HIT for DIC (which drops platelets far lower and prolongs coagulation), transfusing platelets prophylactically (unnecessary — bleeding is rare in HIT), and forgetting that low-molecular-weight heparin is contraindicated as the substitute — the antibody cross-reacts, and only a genuinely non-heparin agent qualifies. The viva favourite is the paradox itself: why a thrombocytopenic patient thromboses — because the antibody activates platelets through Fc receptors rather than destroying them passively. The Indian reality: unfractionated and low-molecular-weight heparin are among the most-used parenteral drugs in Indian wards — post-operatively, in pregnancy, on dialysis — so the suspicion threshold matters daily, while confirmatory serotonin release assays exist only in reference laboratories, making empiric switching standard practice. Argatroban availability is patchy outside tertiary centres; fondaparinux and the direct oral anticoagulants carry the practical load. One extra Indian caution: tuberculosis treatment with rifampicin under NTEP induces hepatic enzymes and complicates argatroban-warfarin sequencing in these often elderly, comorbid patients — the drug chart deserves a full read before the anticoagulation plan is written.
Frequently asked questions
On which days of heparin exposure does classic heparin-induced thrombocytopenia appear?
Between days 5 and 10 — earlier within 24 hours if antibodies persist from exposure in the preceding weeks.
Which test is the confirmatory gold standard?
The serotonin release assay, with the PF4-heparin IgG ELISA as the standard screening immunoassay, both interpreted alongside the 4Ts score.
Why must warfarin be delayed until platelet recovery?
Early vitamin K antagonism depletes protein C, precipitating venous limb gangrene and warfarin skin necrosis — warfarin starts only at platelets of 150 x 10^9/L or more with a five-day overlap.
Which non-heparin anticoagulant suits a patient with renal failure?
Argatroban, cleared hepatically — remembering that it artefactually prolongs the INR, complicating the later warfarin transition.
Why is thrombosis, rather than bleeding, the clinical signature?
The PF4-heparin antibody cross-links platelet Fc receptors and activates them, generating a prothrombotic state despite the falling count.
Can heparin ever be given again after heparin-induced thrombocytopenia?
Yes — antibodies typically clear within months to about a year, allowing brief intra-operative re-exposure in cardiac surgery once testing is negative.